logo

Sellas Life Sciences Group, Inc. (SLS)



Trade SLS now with
  Date
  Headline
2/14/2020 8:41:55 AM SELLAS Life Sciences Announces Feedback From A Type C Review With FDA
2/11/2020 8:37:42 AM SELLAS Enrolls First Patient In Phase 1 Trial Of Galinpepimut-S In Combination With Nivolumab
2/10/2020 8:54:36 AM SELLAS Life Sciences Appoints Dragan Cicic SVP, Clinical Development
1/9/2020 9:08:08 AM SELLAS Reports Pricing Of $6.5 Mln Direct Offering
6/14/2019 9:06:02 AM SELLAS Life Sciences Reports Pricing Of $15 Mln Public Offering
1/8/2019 8:34:58 AM SELLAS Life Sciences Provides Update On Late-Stage Immunotherapy Clinical Development Pipeline
11/28/2018 8:40:00 AM SELLAS Reports Expedited Development Path For Galinpepimut-S In AML Following Feedback From FDA
11/9/2018 8:59:20 AM SELLAS Reports Additional Data Showing Consistent Clinical Effect Across HLA Allele Subgroups
11/9/2018 8:39:49 AM SELLAS Reports Settlement Of Counterclaims Against JGB (Cayman) Newton, Ltd. For $6.6 Mln Payment By JGB
10/22/2018 7:21:36 AM SELLAS Life Sciences Presents Positive Final Data From Phase 2b Clinical Trial Of Nelipepimut-S With Trastuzumab At ESMO
10/19/2018 8:14:11 AM SELLAS Life Sciences : Data Safety Monitoring Board Confirms Triple Negative Breast Cancer
9/13/2018 8:37:59 AM SELLAS Gets Orphan Medicinal Product Designation Approval By COMP For Galinpepimut-S For Treatment Of Multiple Myeloma
8/15/2018 8:11:48 AM SELLAS Life Sciences Q2 Loss Attributable To Stockholders $8.5 Mln Or $1.26/Shr Vs Loss $5.9 Mln Or $4.50/Shr Last Year
7/23/2018 8:41:23 AM SELLAS Life Sciences To Present Data From Phase 2b Trial Of NeuVax + Herceptin At ESMO 2018 Meeting